Status:
WITHDRAWN
Study of Eltrombopag in Platelet Refractory Thrombocytopenia
Lead Sponsor:
University of Cincinnati
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Thrombocytopenia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This phase II trial is studying the effects of the drug eltrombopag has on thrombocytopenia (low platelet count). Eltrombopag is approved by the FDA for the treatment of thrombocytopenia (low platelet...
Eligibility Criteria
Inclusion
- Laboratory diagnosis of platelet refractoriness
- Diagnosis of platelet dependence
- Adequate liver and renal laboratory screening tests
Exclusion
- Patients with thrombocytopenia that are responsive to platelet therapy
- Patients actively receiving intravenous immunoglobulin, plasmapheresis or cytotoxic medications for thrombocytopenia
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01194167
Start Date
August 1 2010
End Date
January 1 2012
Last Update
November 25 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Cincinnati
Cincinnati, Ohio, United States, 45219